One Protein, At Least Three Structures, and Many Functions  by Zlotnick, Adam et al.
Structure
PreviewsThe data is a good illustration of the
propensity of SSBPs to interact with nu-
cleic acids via adaptations of the protein
binding interface and/or of the ssDNA.
Interestingly, similar adaptations were
observed in some RNA recognition motifs
(RRMs), structures bound to RNA. Most
recently, it was shown by NMR that the
human protein SRSF2 can specifically
recognize equally well 50-GGNG-30 and
50-CCNG-30 (N is for any nucleotide)
sequences using almost the same
network of hydrogen bonds (Figure 1B)
(Daubner et al., 2012). In the 50-GGNG-30
complex, the two first guanines adopt
a syn conformation exposing their Hoogs-
teen faces to the protein binding surface,
while in the 50-CCNG-30, the two cyto-
sines adopt an anti conformation, expos-
ing their Watson-Crick edges (Daubner
et al., 2012). Similarly, an adenine in a
syn conformation can be adopted instead
of a uracil in the structure of HuD in
complex with RNA (Wang and Tanaka
Hall, 2001). As a last example, one could
also mention the cold shock domain of
Lin28, which adopts a structure very
similar to an OB-fold and binds ssRNAs6 Structure 21, January 8, 2013 ª2013 Elseviwith only limited sequence specificity,
because it can adapt its mode of interac-
tion to different RNA targets (Figure 1C)
(Nam et al., 2011).
This high versatility of SSBP interac-
tions with nucleic acids makes the predic-
tion of their sequence-specificity or their
in silico modeling difficult and questions
if one might be able to decipher a code
for nucleic acid recognition by SSPBs
(Auweter et al., 2006). Structure determi-
nation combined with affinity measure-
ments using mutated protein and nucleic
acid partners remains the best approach
to firmly establish if a mode of nucleic-
acid recognition is sequence-specific or
not, as sequence-specificity on the
sole basis of high-resolution structures
appears clearly to be insufficient.
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Hepatitis B virus core gene products can adopt different conformations to perform their functional roles. In
this issue ofStructure, DiMattia and colleagues show the crystal structure of immuno-modulating HBeAg and
thereby reveal the similarities and differences between it and HBcAg, the variant found in virions.How can one protein generate two
distinct immune responses and be en-
dowedwith at least two unique functions?
Some proteins achieve multiple functions
through intrinsically disordered regions,
others by subtle allosteric shifts. The
Hepatitis B virus (HBV) core protein
undergoes a radical reorientation of its
dimer interface; it is a striking example
of Gregorio Weber’s characterizationthat a protein is a ‘‘kicking, screaming,
stochastic molecule.’’
HBV chronically infects 360 million
people. It has a unique ability to establish
virus-specific immuno-tolerance while
continually producing infectious virus
particles. The core gene, the source of
‘‘e’’ and ‘‘c’’ antigens, plays both sides of
this street. The ‘‘c’’ antigen (HBcAg) is a
homodimeric protein that self-assemblesto package viral RNA and reverse tran-
scriptase; this complex is the HBV core.
The ‘‘e’’ antigen (HBeAg) translation
begins at an upstream methionine so
that it includes a signal sequence that
leads it to be secreted after proteolytic
processing of the signal and removal of
theRNA-bindingC terminus. The resulting
HBeAg sequence thus includes a 10
amino acid propeptide. While HBcAg
Figure 1. HBV Core Protein Dimers Have Different Structures that Reflect Their Activities
Themonomer structure is very similar in all three known states, with some changes evident in the helices that make the dimer interface (helix 3, green; helix 4, light
orange). In HBeAg (3V6Z), Cys(7) in the propeptide (magenta spheres) disulfide crosslinks with Cys61 (yellow spheres). In free HBcAg dimer (3KXS) and HBcAg
from capsid (1QGT) (assembly-inactive and assembled states, respectively), which lack the propeptide, the second subunit is rotated 140 compared to HBeAg.
In HBcAg, there is an intradimer Cys61-Cys61 disulfide. Structures are colored as in DiMattia et al. (2013).
Structure
Previewscapsids are highly antigenic, HBeAg is
implicated in attenuating immune
response to chronic infection but is
entirely dispensable for virus assembly
and replication (Chen et al., 2005; Seeger
et al., 2007).
In this issue of Structure, DiMattia et al.
(2013) present the structure of HBeAg to
explain the basis of the similarities and
differences between HBeAg and HBcAg.
Both HBcAg and HBeAg have dimeric
forms. A monomer is comprised of five
helices. The helix 3-helix 4 hairpin dimer-
izes with a second monomer to form
a central helical bundle (DiMattia et al.,
2013; Wynne et al., 1999). This dimer
interface is the fulcrum for changes in
structure and activity. In the context of
a capsid, the dimer interface is symmet-
rical (rightmost panels of Figure 1); helix
5 and the following amino acids (pale
red) form interdimer contacts (Wynne
et al., 1999). Free HBcAg dimers have
a notably different structure where the in-
tradimer helical bundle is distorted, which
results in helix 5 adopting a geometryincompatible with forming an icosahedral
capsid (middle panels of Figure 1) (Pack-
ianathan et al., 2010). It has been hypoth-
esized that the dimer interface of HBcAg
undergoes anallosteric change to activate
assembly (Bourne et al., 2009). In free and
capsid forms, HBcAg can form a Cys61-
Cys61 disulfide connecting the two
monomers. In the HBeAg structure, the
monomer structure is very similar to the
HBcAg monomer, but the dimer interface
is completely remodeled. The second
subunit is rotated by 140 around an axis
near the top of helix 3. This structure is
stabilized by a novel disulfide between
Cys(7) of the propeptide (magenta, left-
most panels of Figure 1) and Cys61.
Where HBcAg readily assembles into
T = 4 or T = 3 capsids, HBeAg with the
Cys61 – Cys(7) disulfide is locked in
a structure that cannot assemble. Also,
the major HBcAg epitope, the spike tip
formed by the dimer interface, is com-
pletely disrupted in the Cys61 – Cys(7)
HBeAg structure. The smaller buried
surface of the HBeAg interface suggestsStructure 21, January 8, 20that it is in a less stable state that is locked
down by the disulfide (the melting temper-
ature of HBeAg is 14C lower than that of
oxidized free HBcAg; Watts et al., 2011).
Fantastically,when theHBeAg intra-mono-
mer Cys61 – Cys(7) disulfide is reduced,
the resulting protein readily assembles
into morphologically normal capsids indi-
cating HBeAg can adopt an HBcAg-like
conformation (DiMattia et al., 2013; Watts
et al., 2011).
The ability of HBeAg to flip from its
assembly-incompetent form to one that
is consistent with HBcAg demonstrates
that these are tremendously dynamic
structures. To adopt both e and c confor-
mations, the reduced protein must switch
between at least these two states. This
flexibility is also consistent with allosteric
activation of capsid assembly. Support-
ing this assertion, the F97L mutation at
the dimer interface enhances capsid
assembly compared to wild-type protein
and leads to defects in virus secretion in
cell culture (Ceres et al., 2004; Le Pogam
et al., 2000; Yuan et al., 1999).13 ª2013 Elsevier Ltd All rights reserved 7
Structure
PreviewsThe findings of DiMattia et al. (2013)
suggest a possible explanation for the
conservation of the Cys61 and Cys(7)
in all genotypes of HBV by proposing
a dual function for Cys61. It can be
hypothesized that formation of the
Cys61-Cys61 disulfide bond increases
the stability of the HBcAg dimer and/or
capsid. While formation of the Cys(7)-
Cys61 disulfide bond prevents assembly
of HBeAg, creating a structurally distinct
molecule that is able to suppress immune
response to HBV, it provides an evolu-
tionary advantage for virus replication
(Chen et al., 2005; Seeger et al., 2007).
The dynamic structure of HBeAg/HBcAg
not only regulates capsid assembly, but8 Structure 21, January 8, 2013 ª2013 Elsevialso preserves different functional roles
of the core protein gene products in other
steps of the virus life cycle.REFERENCES
Bourne, C.R., Katen, S.P., Fulz, M.R., Packiana-
than, C., and Zlotnick, A. (2009). Biochemistry 48,
1736–1742.
Ceres, P., Stray, S.J., and Zlotnick, A. (2004). J.
Virol. 78, 9538–9543.
Chen, M., Sa¨llberg, M., Hughes, J., Jones, J., Gui-
dotti, L.G., Chisari, F.V., Billaud, J.N., and Milich,
D.R. (2005). J. Virol. 79, 3016–3027.
DiMattia, M.A., Watts, N.R., Stahl, S.J., Grimes,
J.M., Steven, A.C., Stuart, D.I., and Wingfield,
P.T. (2013). Structure 21, this issue, 133–142.er Ltd All rights reservedLe Pogam, S., Yuan, T.T., Sahu, G.K., Chatterjee,
S., and Shih, C. (2000). J. Virol. 74, 9099–9105.
Packianathan, C., Katen, S.P., Dann, C.E., 3rd, and
Zlotnick, A. (2010). J. Virol. 84, 1607–1615.
Seeger, C., Zoulim, F., and Mason, W.S. (2007).
Hepadnaviruses. In Fields Virology, D.M. Knipe,
D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman,
and S.E. Straus, eds. (Philadelphia: Lippincott Wil-
liams & Wilkins), pp. 2977–3029.
Watts, N.R., Conway, J.F., Cheng, N., Stahl, S.J.,
Steven, A.C., and Wingfield, P.T. (2011). J. Mol.
Biol. 409, 202–213.
Wynne, S.A., Crowther, R.A., and Leslie, A.G.
(1999). Mol. Cell 3, 771–780.
Yuan, T.T., Sahu, G.K., Whitehead, W.E., Green-
berg, R., and Shih, C. (1999). J. Virol. 73, 5731–
5740.
